1. Update on current pharmacologic therapies for diabetic retinopathy.
- Author
-
Muns SM, Villegas VM, Flynn HW Jr, and Schwartz SG
- Subjects
- Humans, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Glucocorticoids therapeutic use, Intravitreal Injections, Diabetic Retinopathy drug therapy, Diabetic Retinopathy complications, Macular Edema drug therapy, Macular Edema etiology, Diabetes Mellitus drug therapy
- Abstract
Introduction: Diabetic retinopathy is a major cause of visual loss worldwide. The most important clinical findings include diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR)., Areas Covered: PubMed was used for our literature review. Articles from 1995 to 2023 were included. Pharmacologic treatment of diabetic retinopathy generally involves the use of intravitreal anti-vascular endothelial growth factor (VEGF) therapy for DME and PDR. Corticosteroids remain important second-line therapies for patients with DME. Most emerging therapies focus on newly identified inflammatory mediators and biochemical signaling pathways involved in disease pathogenesis., Expert Opinion: Emerging anti-VEGF modalities, integrin antagonists, and anti-inflammatory agents have the potential to improve outcomes with reduced treatment burdens.
- Published
- 2023
- Full Text
- View/download PDF